CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Surface Oncology - SURF CFD

    1.05
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Surface Oncology Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.05
    Open* 1.02
    1-Year Change* -21.54%
    Day's Range* 0.99 - 1.05
    52 wk Range 0.56-1.43
    Average Volume (10 days) 466.36K
    Average Volume (3 months) 16.51M
    Market Cap 65.08M
    P/E Ratio -100.00K
    Shares Outstanding 60.82M
    Revenue N/A
    EPS -1.54
    Dividend (Yield %) N/A
    Beta 1.74
    Next Earnings Date Oct 31, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 7, 2023 1.05 0.03 2.94% 1.02 1.05 0.99
    Sep 6, 2023 1.05 0.07 7.14% 0.98 1.08 0.98
    Sep 5, 2023 0.99 -0.06 -5.71% 1.05 1.05 0.98
    Sep 1, 2023 1.06 0.02 1.92% 1.04 1.08 1.02
    Aug 31, 2023 1.05 0.03 2.94% 1.02 1.06 1.01
    Aug 30, 2023 1.04 0.02 1.96% 1.02 1.06 1.02
    Aug 29, 2023 1.03 0.07 7.29% 0.96 1.04 0.96
    Aug 28, 2023 0.98 0.03 3.16% 0.95 0.98 0.92
    Aug 25, 2023 0.93 0.02 2.20% 0.91 0.93 0.91
    Aug 24, 2023 0.93 0.02 2.20% 0.91 0.93 0.89
    Aug 23, 2023 0.92 0.00 0.00% 0.92 0.96 0.92
    Aug 22, 2023 0.89 -0.01 -1.11% 0.90 0.92 0.87
    Aug 21, 2023 0.90 0.02 2.27% 0.88 0.92 0.87
    Aug 18, 2023 0.88 0.05 6.02% 0.83 0.89 0.83
    Aug 17, 2023 0.86 -0.02 -2.27% 0.88 0.89 0.85
    Aug 16, 2023 0.88 -0.01 -1.12% 0.89 0.90 0.88
    Aug 15, 2023 0.89 0.01 1.14% 0.88 0.89 0.86
    Aug 14, 2023 0.88 -0.02 -2.22% 0.90 0.91 0.87
    Aug 11, 2023 0.91 -0.01 -1.09% 0.92 0.92 0.90
    Aug 10, 2023 0.92 0.02 2.22% 0.90 0.94 0.90

    Surface Oncology Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Surface Oncology Inc Earnings Release
    Q4 2023 Surface Oncology Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 30 2.687 126.162 15.36 59.417
    Revenue 30 2.687 126.162 15.36 59.417
    Total Operating Expense 91.869 78.7 66.825 70.149 66.014
    Selling/General/Admin. Expenses, Total 27.635 27.769 25.669 23.627 16.076
    Research & Development 64.234 50.931 38.907 49.099 52.492
    Interest Expense (Income) - Net Operating 2.249 -2.577 -2.554
    Operating Income -61.869 -76.013 59.337 -54.789 -6.597
    Net Income Before Taxes -63.586 -78.485 59.337 -54.789 -6.597
    Net Income After Taxes -63.586 -78.485 59.337 -54.789 -6.597
    Net Income Before Extra. Items -63.586 -78.485 59.337 -54.789 -6.597
    Net Income -63.586 -78.485 59.337 -54.789 -6.597
    Total Adjustments to Net Income 0 0 -0.011
    Income Available to Common Excl. Extra. Items -63.586 -78.485 59.337 -54.789 -6.608
    Income Available to Common Incl. Extra. Items -63.586 -78.485 59.337 -54.789 -6.608
    Diluted Net Income -63.586 -78.485 59.337 -54.789 -6.608
    Diluted Weighted Average Shares 55.7614 44.2433 38.1418 27.8549 19.9908
    Diluted EPS Excluding Extraordinary Items -1.14032 -1.77394 1.5557 -1.96694 -0.33055
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -1.14032 -1.77394 1.5557 -1.96691 -0.32985
    Interest Income (Expense), Net Non-Operating -3.146 -2.546
    Other, Net 1.429 0.074
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 25.641 19.663 21.184 22.898 24.624
    Selling/General/Admin. Expenses, Total 8.576 5.886 5.896 6.004 6.426
    Research & Development 13.831 13.777 15.288 16.894 18.198
    Operating Income -25.641 -19.663 -21.184 -22.898 -24.624
    Interest Income (Expense), Net Non-Operating -3.108 -0.932 -0.902 -0.829 -0.733
    Other, Net 0.557 0.854 0.754 0.487 0.144
    Net Income Before Taxes -28.192 -19.741 -21.332 -23.24 -25.213
    Net Income After Taxes -28.192 -19.741 -21.332 -23.24 -25.213
    Net Income Before Extra. Items -28.192 -19.741 -21.332 -23.24 -25.213
    Net Income -28.192 -19.741 -21.332 -23.24 -25.213
    Income Available to Common Excl. Extra. Items -28.192 -19.741 -21.332 -23.24 -25.213
    Income Available to Common Incl. Extra. Items -28.192 -19.741 -21.332 -23.24 -25.213
    Diluted Net Income -28.192 -19.741 -21.332 -23.24 -25.213
    Diluted Weighted Average Shares 60.7179 60.628 60.6154 59.0545 54.6548
    Diluted EPS Excluding Extraordinary Items -0.46431 -0.32561 -0.35192 -0.39353 -0.46131
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.41105 -0.32561 -0.35192 -0.39353 -0.46131
    Dilution Adjustment
    Unusual Expense (Income) 3.234
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 129.14 157.346 180.509 107.926 164.601
    Cash and Short Term Investments 124.823 154.149 175.141 105.161 158.835
    Cash & Equivalents 50.91 56.045 175.141 46.755 82.912
    Short Term Investments 73.913 98.104 0 58.406 75.923
    Total Receivables, Net 0.197 0.765 2.571 0.336 1.246
    Prepaid Expenses 4.12 2.432 2.797 2.429 4.52
    Other Current Assets, Total 0
    Total Assets 159.91 190.847 217.138 131.693 174.065
    Property/Plant/Equipment, Total - Net 29.173 31.521 34.575 22.144 8.226
    Property/Plant/Equipment, Total - Gross 38.29 39.274 40.759 26.658 10.959
    Accumulated Depreciation, Total -9.117 -7.753 -6.184 -4.514 -2.733
    Other Long Term Assets, Total 1.597 1.98 2.054 1.623 1.238
    Total Current Liabilities 16.26 20.023 17.651 19.274 27.177
    Accounts Payable 0.256 1.55 1.674 3.384 3.412
    Accrued Expenses 13.858 15.235 14.929 10.22 8.263
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.146 3.238 1.048 5.67 15.502
    Total Liabilities 66.507 71.947 61.391 75.027 71.203
    Total Long Term Debt 25.585 25.015 14.759 5.109 0
    Other Liabilities, Total 24.662 26.909 28.981 50.644 44.026
    Total Equity 93.403 118.9 155.747 56.666 102.862
    Redeemable Preferred Stock 0 0
    Common Stock 0.006 0.005 0.004 0.003 0.003
    Additional Paid-In Capital 298.741 259.859 218.001 178.155 169.784
    Retained Earnings (Accumulated Deficit) -204.329 -140.743 -62.258 -121.595 -66.806
    Other Equity, Total -1.015 -0.221 0 0.103 -0.119
    Total Liabilities & Shareholders’ Equity 159.91 190.847 217.138 131.693 174.065
    Total Common Shares Outstanding 60.579 46.9588 40.7071 27.8933 27.7726
    Preferred Stock - Non Redeemable, Net 0 0 0
    Long Term Debt 25.585 25.015 14.759 5.109
    Accounts Receivable - Trade, Net 0 0.518 2.571
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 107.209 129.14 150.122 161.505 184.285
    Cash and Short Term Investments 102.055 124.823 146.35 156.648 150.393
    Cash & Equivalents 28.982 50.91 65.096 74.824 65.657
    Short Term Investments 73.073 73.913 81.254 81.824 84.736
    Prepaid Expenses 5.154 4.317 3.772 4.857 3.892
    Total Assets 137.008 159.91 181.621 193.979 217.68
    Property/Plant/Equipment, Total - Net 28.204 29.173 29.813 30.651 31.395
    Other Long Term Assets, Total 1.595 1.597 1.686 1.823 2
    Total Current Liabilities 14.75 16.26 17.992 19.725 19.561
    Accounts Payable 1.108 0.256 0.535 0.486 2.625
    Accrued Expenses 10.423 16.004 17.457 16.447 16.223
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 3.219 0 2.792 0.713
    Total Liabilities 61.177 66.507 68.802 68.263 70.693
    Total Long Term Debt 22.488 25.585 25.462 22.519 24.448
    Long Term Debt 22.488 25.585 25.462 22.519 24.448
    Other Liabilities, Total 23.939 24.662 25.348 26.019 26.684
    Total Equity 75.831 93.403 112.819 125.716 146.987
    Redeemable Preferred Stock
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.006 0.006 0.006 0.006 0.006
    Additional Paid-In Capital 300.464 298.741 297.179 286.637 282.436
    Retained Earnings (Accumulated Deficit) -224.07 -204.329 -182.997 -159.757 -134.544
    Other Equity, Total -0.569 -1.015 -1.369 -1.17 -0.911
    Total Liabilities & Shareholders’ Equity 137.008 159.91 181.621 193.979 217.68
    Total Common Shares Outstanding 60.7169 60.579 60.5423 55.3849 54.3476
    Total Receivables, Net 0 30
    Accounts Receivable - Trade, Net 0 30
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -63.586 -78.485 59.337 -54.789 -6.597
    Cash From Operating Activities -59.552 -62.344 29.997 -60.14 -13.222
    Cash From Operating Activities 1.368 1.569 1.67 1.785 1.347
    Non-Cash Items 10.254 12.463 11.319 7.116 4.854
    Cash Taxes Paid 0 0 0.028
    Changes in Working Capital -7.588 2.109 -42.329 -14.252 -12.826
    Cash From Investing Activities 22.757 -99.252 58.307 16.965 -36.584
    Capital Expenditures -0.497 -0.12 -0.043 -1.538 -2.019
    Other Investing Cash Flow Items, Total 23.254 -99.132 58.35 18.503 -34.565
    Cash From Financing Activities 31.66 42.5 40.082 7.415 110.376
    Financing Cash Flow Items 0 9.469
    Issuance (Retirement) of Stock, Net 31.66 31.813 30.082 0.279 100.907
    Issuance (Retirement) of Debt, Net 0 10.687 10 7.136 0
    Net Change in Cash -5.135 -119.096 128.386 -35.76 60.57
    Cash Interest Paid 2.476 1.406 1.052
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -19.741 -63.586 -42.254 -19.014 6.199
    Cash From Operating Activities -23.439 -59.552 -37.798 -18.971 -23.566
    Cash From Operating Activities 0.318 1.368 1.037 0.691 0.345
    Non-Cash Items 2.251 10.254 8.153 5.682 2.803
    Cash Interest Paid 1.746 2.476 1.746 1.097 0.531
    Changes in Working Capital -6.267 -7.588 -4.734 -6.33 -32.913
    Cash From Investing Activities 1.434 22.757 15.232 14.909 12.465
    Capital Expenditures -0.017 -0.497 -0.205 -0.146 -0.035
    Other Investing Cash Flow Items, Total 1.451 23.254 15.437 15.055 12.5
    Cash From Financing Activities 0.077 31.66 31.617 22.841 20.713
    Issuance (Retirement) of Stock, Net 0.077 31.66 31.617 22.841 20.713
    Issuance (Retirement) of Debt, Net 0
    Net Change in Cash -21.928 -5.135 9.051 18.779 9.612

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Surface Oncology Company profile

    About Surface Oncology Inc

    Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Its pipeline includes two wholly owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a pre-clinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase I) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Surface Oncology Inc revenues decreased 98% to $2.7M. Net loss totaled $78.5M vs. income of $59.3M. Revenues reflect License-related revenue decrease of 97% to $2.7M, Collaboration revenue - related party decrease from $38.6M to $0K. Net loss reflects Research and development - Balancing increase of 34% to $48.5M (expense), Stock-based Compensation in SGA increase of 24% to $6.1M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    50 Hampshire Street, 8Th Floor
    02139

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    43,836.50 Price
    -0.520% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading